|
Back to Home » April 2019 News » BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance |
BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance |
April 02, 2019
BERGEN, Norway, April 2, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces preclinical data strengthening bemcentinib's broad potential in reversing...
Source URL: https://www.prnewswire.com:443/news-releases/bergenbio-preclinical-data-presented-at-aacr-reinforces-bemcentinibs-potential-to-reverse-tumour-immunosuppression-and-therapy-resistance-300822529.html
|
|
|
|
